Sentences with phrase «than patients in»

Clinical improvement was achieved by more patients who received CBT than patients in the other 2 groups combined (p = 0.02)(table ⇓).

Patients in the family intervention group had better functioning on activities of daily living than patients in the 2 control groups, but did not differ for cognitive function, depression, psychotic symptoms, behavioural disturbances, or overall severity of dementia.

Patients with high negative affect dropped out of BWL (46 %) more often than patients in CBTgsh did (24 %), whereas the pattern was reversed among the patients with low negative affect (BWL, 14 %; CBTgsh, 35 %).

In one study, hospital patients in rooms with indoor plants reported less stress than patients in rooms with a painting on the wall.

For example, people who were taking only an inactive placebo were more likely than patients in other groups to drop out of study, suggesting these families had noticed the placebo «medication» wasn't working.

Patients in a minimally conscious state (MCS) fall into an importantly different diagnostic category than patients in the more familiar vegetative sta...

«Americans with cancer pay 50 percent to 100 percent more for the same patented drug than patients in other countries,» says S. Vincent Rajkumar, M.D., of Mayo Clinic Cancer Center, who is one of the authors.

«I think if we go back and check our record, the Negro has proven beyond a doubt that we have been more than patient in seeking our rights as American citizens.»

Not exact matches

It's better to drown patients in paperwork than foot the bill themselves.

In addition, enabling primary care providers to see patients, rather than sending them off to specialists straight away, could help lower healthcare costs for payers.

MedStar operates 10 hospitals in the D.C. / Baltimore region, including at Georgetown University, and serviced more than 4.5 million patient visits in 2015.

Because it makes up more than 13 % of all new cancers and nearly 27 % of all cancer deaths in the U.S. Just 17.7 % of diagnosed patients are still alive five years out from their diagnosis.

British - based GlaxoSmithKline, for example, conducts more than 100 studies a year in Canada, with the participation of some 10,500 patients in more than 1,000 medical centres.

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

Then they tested the product in homes, where more than 80 percent of dementia patients live.

Because Hopewell is privately owned, it can be more patient than many of its publicly traded competitors in pursuing its objectives; as Kraatz puts it, «we prioritize repeat clients and long - term success over short - term, bottom - line victories.»

In this new system, healthcare is evolving to become proactive rather than reactive, allowing patients to potentially catch and treat problems earlier.

It's not a blockbuster, but Sirturo is saving lives: the drug, which was added to the World Health Organization's Essential Medicines List in 2015, has been registered in over 40 countries and used to treat more than 10,000 patients.

Through its more than 9,800 retail locations, more than 1,100 walk - in medical clinics, a leading pharmacy benefits manager with more than 94 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand - alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways.

Patients who experienced the VR coastal scene reported having «significantly less pain» than those in the other two groups.

More than 2,600 drugs have some stage of manufacture in Britain and 45 million patient packs are supplied from the U.K. to other European countries each month, while another 37 million flow in the opposite direction.

But in medicine, impressive technology is little more than a parlor trick if it doesn't benefit patients — like James (who asked to keep his last name private), a 42 - year - old colon cancer patient who had part of his large intestine removed by Sullivan a few months ago.

In the past five years alone, they have cared for more than 42,000 patients.

For more than 80 years, patients have relied upon Board Certification as an indicator that their physician is current in their expertise and prioritizes quality care.

The U.S. Patent Office granted Myriad's patent for the two genes and the assay in 1997 and more than 250,000 patients have used Myriad for BCRA1 and BCRA2 gene testing.

We have to fund innovations, we have to seed new ways of doing things and we have to get them in place so we can get the money out of the system that is being spent unnecessarily today without getting good results for patients and is causing more complexity than necessary.»

One setback for these therapies which use the body's immune system to fight cancers is that they are, at times, more effective in certain patient pools than others.

Intarcia has completed several late - stage clinical trials in which it uses the pump to deliver a glucose - controlling drug continuously for months — an idea, that if successful (and approved by the FDA) could significantly help patients with type 2 diabetes, fewer than half of whom maintain the recommended glycemic levels.

The study, just published in Science, showed that the creation of what the researchers are calling microtumors can help predict drug effectiveness in cancer patients better than the current standard method of testing the drugs on rodents.

In plainer terms, the researchers are arguing for a preventive approach that's based on changes in internal biology rather than the behavioral and physical symptoms which plague Alzheimer's patients and are visible to the non-clinical world, including friends and family memberIn plainer terms, the researchers are arguing for a preventive approach that's based on changes in internal biology rather than the behavioral and physical symptoms which plague Alzheimer's patients and are visible to the non-clinical world, including friends and family memberin internal biology rather than the behavioral and physical symptoms which plague Alzheimer's patients and are visible to the non-clinical world, including friends and family members.

Amgen unveiled some promising news during the American Heart Association's annual meeting involving its next - gen cholesterol - busting medication Repatha, which has been shown to significantly reduce the level of «bad» cholesterol in patients, announcing that more than 60 % of patients who were receiving the therapy in a trial had a reduction in arterial plaque.

That's not just because of Opdivo's failure — last month, Keytruda was shown to be better than standard chemotherapy in untreated advanced lung cancer patients with high levels of the PD - L1 protein, both stopping cancer progression and extending patients» lives.

Patients can usually get feedback from the doctor within minutes, and often for the same price or less than an in - person doctor's office or urgent - care clinic visit.

Researchers Debra Roter and Judith Hall have suggested that differences in patient communication and attentiveness may play a role: In one analysis, in fact, female physicians spent two minutes (10 %) longer with patients than male doctors diin patient communication and attentiveness may play a role: In one analysis, in fact, female physicians spent two minutes (10 %) longer with patients than male doctors diIn one analysis, in fact, female physicians spent two minutes (10 %) longer with patients than male doctors diin fact, female physicians spent two minutes (10 %) longer with patients than male doctors did.

Upon discharge from the hospital, more than 25 percent of SCI patients have complete paraplegia, meaning they are unable to feel or move their legs; more than 20 percent suffer from complete tetraplegia, or paralysis in all four limbs and the torso.

Only about 200 patients or fewer will take Valeant's branded version of the migraine drug this year, amounting to less than $ 1 million in sales (about 0.01 % of the company's annual revenue).

At one eating - disorder treatment clinic in New York City, more than half the patients report having tried a juice cleanse, Marie Claire reports.

Approach a condition from the position of «Tell me what's bothering you» rather than «Tell me what you have,» Bertolini said, and you might convince a patient to hand over personal data in pursuit of a solution to what ultimately irks them.

While Yervoy brought in $ 960 million in sales in 2013 (an enormous figure for a two - year - old drug with a small patient population), the company currently has more than 35 ongoing clinical trials investigating another drug that disengages the immune system's brakes: the much - awaited nivolumab, which was also from the Medarex portfolio.

There were more than 235,000 medical marijuana patients in the system across Canada at the end of September 2017, compared to roughly 98,500 a year earlier, noted Vahan Ajamian, a Beacon Securities Ltd. research analyst.

Love is supposed to be patient and grounded in honesty, but, at times, these two signs can struggle to express those attributes: Aries is more closely associated with rapid decisiveness than it is with measured, thoughtful actions.

«Liquid biopsies are far less invasive than traditional biopsies, a development that not only benefits our patients through a simplified diagnostic procedure but also by significantly enhanced analysis of samples taken,» said Dr. Stanley Hamilton, professor of Pathology and division head of Pathology and Laboratory Medicine at MD Anderson, in a statement.

Patients who enrolled in BCBS individual plans in 2014 and 2015 have higher rates of certain diseases — depression, hypertension, diabetes, coronary artery disease, HIV and hepatitis C — than individuals enrolled in coverage prior to ACA implementation.

The command center pulls in information from more than a dozen data streams in real time, including patient health records, emergency dispatch service updates, lab results, and tabs on how many hospital beds are available at any given time.

Final patient visits will be followed by completing data entry for the more than 35,000 patient years of study in REDUCE - IT, and typical database quality control measures, known as cleaning.

Giving customers (patients in this case) what they want in the moment rather than what will help them the most could destroy any long - term satisfaction.

To see what the new balance of power will look like in the coming years — and what it looks like right now — Fortune interviewed more than three dozen executives at companies across the health care continuum, along with entrepreneurs, doctors, patients, and other experts.

If it works, it could be used in a far greater number of patients than Sarepta's drug, which is approved for a relatively small slice of the DMD patient pool.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Since massive Hurricane Maria struck in September and knocked out the dialysis center on the tiny satellite island of Vieques, more than a dozen patients needing treatment now must fly several times a week to the main island.